AbbVie Inc. UNDER RULE 8.1
03 Aprile 2020 - 8:00AM
UK Regulatory
TIDM0QCV
AbbVie Inc. - Form 8.1 - Dealings By Offerors, Offerees Or Parties Acting In
Concert With Them For Themselves Or For Discretionary Clients
NORTH CHICAGO, Ill., April 2, 2020 --
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i)
OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES
ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS
1. KEY INFORMATION
Name of person dealing (Note 1) Edward Liddy
Company dealt in AbbVie Inc.
Class of relevant security to which the Common shares, par value
dealings being disclosed relate (Note 2) $0.01 per share
Date of dealing 31 March 2020
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing)
in the class of relevant security dealt in (Note 3)
Long Short
Number (%) Number (%)
(1) Relevant securities 22,669 (0.002%)
(2) Derivatives (other than options) 25,118 (0.002%)
(3) Options and agreements to purchase/sell N/A
Total 47,787 (0.003%)
(b)
Interests and short positions in relevant securities of the company, other than the class dealt in
(Note 3) N/A
Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 5)
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD (Note 6) (Note 7) (Note 5)
Stock Director fee credit 426 $76.19
equivalent to stock equivalent
unit unit account
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, purchasing, varying etc. Number of securities to which the option relates Exercise price Type, e.g. American, European etc. Expiry date Option money paid/
e.g. call option (Note 7) received per unit
(Note 5)
(ii) Exercising
Product name, Number of securities Exercise price per unit
e.g. call option (Note 5)
(d) Other dealings (including transactions in respect of new securities)
(Note 4)
Nature of transaction (Note 8) Details Price per unit (if applicable) (Note 5)
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which
any derivative referred to on this form is referenced. If none, this should be
stated.
Is a Supplemental Form 8 attached? (Note 9)
YES/NO?
Date of disclosure 2 April 2020
Contact name Steven L. Scrogham
Telephone number 847-938-6166
Name of offeree/offeror with which acting in concert AbbVie Inc.
Specify category and nature of acting in concert status Director of AbbVie Inc.
SOURCE AbbVie
CONTACT: Adelle Infante, 1-847-938-8745
END
(END) Dow Jones Newswires
April 03, 2020 02:00 ET (06:00 GMT)
Grafico Azioni Abbvie (LSE:0QCV)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Abbvie (LSE:0QCV)
Storico
Da Mag 2023 a Mag 2024
